Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 457-461

  Emons, Günter ^a   Kaufmann, Manfred ^b   Gorchev, Grigor ^c   Tsekova, Valentina ^d   Gründker, Carsten ^a   Günthert, Andreas R ^a,g   Hanker, Lars C ^b   Velikova, Maya ^d   Sindermann, Herbert ^e   Engel, Jürgen ^e   Schally, Andrew V ^f  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c University Hospital Dr Georgi Stransky   (Bulgaria)

^d UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^e Zentaris GmbH   (Germany)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

AESZ 108; AN 152; Doxorubicin; LHRH receptors; Targeted chemotherapy

Indexed keywords

GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ENDOMETRIUM CANCER; ERYTHEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN ALLERGY; SPLEEN DISEASE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROCORTISONE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OVARIAN NEOPLASMS; PITUITARY GLAND; RECEPTORS, LHRH;

EID: 78149359898     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.003     Document Type: Article

References (17)

1. R. Abou-Jawde, T. Choueiri, C. Alemany, and T. Mekhail An overview of targeted treatments in cancer Clin Ther 25 2003 2121 2137
2. G. Emons, and A.V. Schally The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancer Hum Reprod 9 1994 1364 1379
3. A. Nagy, A.V. Schally, P. Armatis, K. Szepeshazi, G. Halmos, and M. Kovacs Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent Proc Natl Acad Sci USA 93 1996 7269 7273
4. S. Buchholz, G. Keller, A.V. Schally, G. Halmos, F. Hohla, and E. Heinrich Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations Proc Natl Acad Sci USA 103 2006 10403 10407
5. A.V. Schally, and A. Nagy Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors Eur J Endocrinol 141 1999 1 14
6. A.V. Schally, A.M. Comaru-Schally, A. Nagy, M. Kovacs, K. Szepeshazi, and A. Plonowski Hypothalamic hormones and cancer Front Neuroendocrinol 22 2001 248 291
7. A.V. Schally New approaches to the therapy of various tumors based on peptide analogues Horm Metab Res 40 2008 315 322
8. A.M. Bajo, A.V. Schally, G. Halmos, and A. Nagy Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers Clin Cancer Res 9 2003 3742 3748
9. G. Halmos, A. Nagy, N. Lamharzi, and A.V. Schally Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers Cancer Lett 136 1999 129 136
10. K. Szepeshazi, A.V. Schally, and A. Nagy Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs Breast Cancer Res Treat 56 1999 267 276
11. S. Westphalen, G. Kotulla, F. Kaiser, W. Krauss, G. Werning, and H.P. Elsasser Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines Int J Oncol 17 2000 1063 1069
12. C. Gründker, P. Völker, F. Griesinger, A. Ramaswamy, A. Nagy, and A.V. Schally Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice Am J Obstet Gynecol 187 2002 528 537
13. A.R. Günthert, C. Gründker, T. Bongertz, A. Nagy, A.V. Schally, and G. Emons Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multi drug resistance-1 (MDR-1) system Breast Cancer Res Treat 87 2004 255 264
14. J.B. Engel, A.V. Schally, J. Dietl, L. Rieger, and A. Hönig Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones Mol Pharm 4 2007 652 658
15. A.R. Günthert, C. Gründker, T. Bongertz, T. Schlott, A. Nagy, and A.V. Schally Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multi drug resistance 1(MDR-1) system Am J Obstet Gynecol 191 2004 1164 1172
16. Adriamycin RDF and PFS prescribing information. http://www.meds.com/ leukemia/idamycin/adriamycin.html. Drawn Jan 2010.
17. American Society of Clinical Oncology, M.G. Kris, P.J. Hesketh, M.R. Somerfield, P. Feyer, and R. Clark-Snow American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2006 2932 2947